Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE M VENEREO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1144299009
CMS profile
324488
Location
DORAL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$95.63

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $95.63 5

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Pharmaceuticals, Inc $68.88 4
Boehringer Ingelheim Pharmaceuticals, Inc. $26.75 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE M VENEREO

NPI 1144299009 · CMS profile ID 324488

Allopathic & Osteopathic Physicians / Internal Medicine

DORAL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144299009?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144299009?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144299009?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1144299009?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $95.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $13.8808/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787921203 CMS
Janssen Pharmaceuticals, Inc $17.8705/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787921205 CMS
Janssen Pharmaceuticals, Inc $17.8705/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787921201 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $26.7503/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763507670 CMS
Janssen Pharmaceuticals, Inc $19.2602/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787921207 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $34.17 2
PY2020 $83.58 5
PY2021 $95.63 5
PY2022 $125.00 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $978,346.35 79
PY2024 Principal investigator $750,186.73 535
PY2023 Recipient $250.00 1
PY2023 Principal investigator $1,161,263.89 753
PY2022 Recipient $450.00 1
PY2022 Principal investigator $433,849.06 425
PY2021 Recipient $437.46 1
PY2021 Principal investigator $229,625.48 182
PY2020 Principal investigator $282,764.54 64
PY2019 Principal investigator $543,958.67 209

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

209 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eisai Inc. $3,827.00 12/31/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530741
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,320.00 12/18/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685013900
Principal investigator 1 AbbVie, Inc. $10,410.60 12/10/2019 Non-covered Recipient Entity
Pharmax Research Clinic
M16-100 No dispute reported 06/30/2026 647588937
Principal investigator 1 Ferring International Pharmascience Center US $1,909.80 12/03/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655228549
Principal investigator 1 AbbVie, Inc. $6,977.20 12/02/2019 Non-covered Recipient Entity
Pharmax Research Clinic
M16-100 No dispute reported 06/30/2026 647588939
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,577.40 11/28/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685013897
Principal investigator 1 AbbVie, Inc. $128.00 11/27/2019 Non-covered Recipient Entity
Pharmax Research Clinic
M16-100 No dispute reported 06/30/2026 647588941
Principal investigator 1 Eisai Inc. $2,280.00 11/26/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530767
Principal investigator 1 Eisai Inc. $2,280.00 11/26/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530769
Principal investigator 1 Eisai Inc. $3,805.00 11/26/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530771
Principal investigator 1 Eisai Inc. $1,625.00 11/26/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530773
Principal investigator 1 Eisai Inc. $2,280.00 11/26/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530775
Principal investigator 1 Eisai Inc. $2,280.00 11/26/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530777
Principal investigator 1 Eisai Inc. $2,280.00 11/26/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530779
Principal investigator 1 Eisai Inc. $4,248.00 11/26/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530781
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $105.03 11/13/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685013887
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,181.20 11/13/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685013891
Principal investigator 1 AbbVie, Inc. $7,055.80 11/12/2019 Non-covered Recipient Entity
Pharmax Research Clinic
M16-100 No dispute reported 06/30/2026 647588945
Principal investigator 1 AbbVie, Inc. $384.00 11/07/2019 Non-covered Recipient Entity
Pharmax Research Clinic
M16-100 No dispute reported 06/30/2026 647588943
Principal investigator 1 Eisai Inc. $3,805.00 10/31/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530743
Principal investigator 1 Eisai Inc. $1,625.00 10/31/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530745
Principal investigator 1 Eisai Inc. $1,625.00 10/31/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530747
Principal investigator 1 Eisai Inc. $1,175.00 10/31/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530749
Principal investigator 1 Eisai Inc. $3,596.00 10/31/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530751
Principal investigator 1 Eisai Inc. $3,805.00 10/31/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530753
Principal investigator 1 Eisai Inc. $1,625.00 10/31/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530755
Principal investigator 1 Eisai Inc. $3,805.00 10/31/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530757
Principal investigator 1 Eisai Inc. $1,625.00 10/31/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530759
Principal investigator 1 Eisai Inc. $3,805.00 10/31/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530761
Principal investigator 1 Eisai Inc. $1,625.00 10/31/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530763
Principal investigator 1 Eisai Inc. $3,805.00 10/31/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530765
Principal investigator 1 AbbVie, Inc. $2,500.00 10/17/2019 Non-covered Recipient Entity
Pharmax Research Clinic
M16-100 No dispute reported 06/30/2026 647588933
Principal investigator 1 AbbVie, Inc. $688.60 10/15/2019 Non-covered Recipient Entity
Pharmax Research Clinic
M16-100 No dispute reported 06/30/2026 647588935
Principal investigator 1 Ferring International Pharmascience Center US $4,365.90 10/02/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655228269
Principal investigator 1 Eisai Inc. $351.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530639
Principal investigator 1 Eisai Inc. $1,625.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530641
Principal investigator 1 Eisai Inc. $1,625.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530643
Principal investigator 1 Eisai Inc. $3,827.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530645
Principal investigator 1 Eisai Inc. $1,625.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530647
Principal investigator 1 Eisai Inc. $1,175.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530649
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530651
Principal investigator 1 Eisai Inc. $1,522.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530653
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530655
Principal investigator 1 Eisai Inc. $351.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530657
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530659
Principal investigator 1 Eisai Inc. $1,522.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530661
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530663
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530665
Principal investigator 1 Eisai Inc. $3,827.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530667
Principal investigator 1 Eisai Inc. $1,625.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530669
Principal investigator 1 Eisai Inc. $3,827.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530671
Principal investigator 1 Eisai Inc. $1,625.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530673
Principal investigator 1 Eisai Inc. $3,827.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530675
Principal investigator 1 Eisai Inc. $1,836.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530677
Principal investigator 1 Eisai Inc. $1,625.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530679
Principal investigator 1 Eisai Inc. $3,827.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530681
Principal investigator 1 Eisai Inc. $1,625.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530683
Principal investigator 1 Eisai Inc. $3,827.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530685
Principal investigator 1 Eisai Inc. $553.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530687
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530689
Principal investigator 1 Eisai Inc. $351.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530691
Principal investigator 1 Eisai Inc. $1,522.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530693
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530695
Principal investigator 1 Eisai Inc. $1,522.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530697
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530699
Principal investigator 1 Eisai Inc. $872.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530701
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530703
Principal investigator 1 Eisai Inc. $1,691.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530705
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530707
Principal investigator 1 Eisai Inc. $553.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530783
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530785
Principal investigator 1 Eisai Inc. $351.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530787
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530789
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530791
Principal investigator 1 Eisai Inc. $1,522.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530793
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530795
Principal investigator 1 Eisai Inc. $872.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530797
Principal investigator 1 Eisai Inc. $1,691.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530799
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530801
Principal investigator 1 Eisai Inc. $1,522.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530803
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530805
Principal investigator 1 Eisai Inc. $351.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530807
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530809
Principal investigator 1 Eisai Inc. $872.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530811
Principal investigator 1 Eisai Inc. $1,522.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530813
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530815
Principal investigator 1 Eisai Inc. $1,522.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530817
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530819
Principal investigator 1 Eisai Inc. $553.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530821
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530823
Principal investigator 1 Eisai Inc. $351.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530825
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530827
Principal investigator 1 Eisai Inc. $1,522.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530829
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530831
Principal investigator 1 Eisai Inc. $1,691.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530833
Principal investigator 1 Eisai Inc. $872.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530835
Principal investigator 1 Eisai Inc. $1,691.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530837
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530839
Principal investigator 1 Eisai Inc. $1,522.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530841
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530843
Principal investigator 1 Eisai Inc. $872.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530845
Principal investigator 1 Eisai Inc. $1,691.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530847
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530849
Principal investigator 1 Eisai Inc. $1,522.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530851
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530853
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530855
Principal investigator 1 Eisai Inc. $872.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530857
Principal investigator 1 Eisai Inc. $1,691.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530859
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530861
Principal investigator 1 Eisai Inc. $553.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530863
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530865
Principal investigator 1 Eisai Inc. $1,522.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530867
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530869
Principal investigator 1 Eisai Inc. $872.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530871
Principal investigator 1 Eisai Inc. $1,691.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530873
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530875
Principal investigator 1 Eisai Inc. $1,522.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530877
Principal investigator 1 Eisai Inc. $1,522.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530879
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530881
Principal investigator 1 Eisai Inc. $1,691.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530883
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530885
Principal investigator 1 Eisai Inc. $553.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530887
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530889
Principal investigator 1 Eisai Inc. $1,522.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530891
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530893
Principal investigator 1 Eisai Inc. $872.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530895
Principal investigator 1 Eisai Inc. $1,691.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530897
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530899
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530901
Principal investigator 1 Eisai Inc. $1,522.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530903
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530905
Principal investigator 1 Eisai Inc. $872.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530907
Principal investigator 1 Eisai Inc. $1,691.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530909
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530911
Principal investigator 1 Eisai Inc. $553.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530913
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530915
Principal investigator 1 Eisai Inc. $1,522.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530917
Principal investigator 1 Eisai Inc. $872.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530919
Principal investigator 1 Eisai Inc. $553.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530921
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530923
Principal investigator 1 Eisai Inc. $1,691.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530925
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530927
Principal investigator 1 Eisai Inc. $553.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530929
Principal investigator 1 Eisai Inc. $75.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530931
Principal investigator 1 Eisai Inc. $3,596.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530933
Principal investigator 1 Eisai Inc. $1,836.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530935
Principal investigator 1 Eisai Inc. $1,836.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530937
Principal investigator 1 Eisai Inc. $1,836.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530939
Principal investigator 1 Eisai Inc. $1,625.00 10/01/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530941
Principal investigator 1 AbbVie, Inc. $2,662.50 09/30/2019 Non-covered Recipient Entity
Pharmax Research Clinic
M16-100 No dispute reported 06/30/2026 647588929
Principal investigator 1 AbbVie, Inc. $640.00 09/17/2019 Non-covered Recipient Entity
Pharmax Research Clinic
M16-100 No dispute reported 06/30/2026 647588931
Principal investigator 1 AbbVie, Inc. $6,242.00 08/29/2019 Non-covered Recipient Entity
Pharmax Research Clinic
M16-100 No dispute reported 06/30/2026 647588925
Principal investigator 1 Ferring International Pharmascience Center US $57,997.80 08/26/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655228003
Principal investigator 1 Ferring International Pharmascience Center US $25,047.90 08/23/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655227939
Principal investigator 1 Eisai Inc. $1,836.00 08/15/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530709
Principal investigator 1 Eisai Inc. $3,818.00 08/15/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530711
Principal investigator 1 Eisai Inc. $1,625.00 08/15/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530713
Principal investigator 1 Eisai Inc. $3,827.00 08/15/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530715
Principal investigator 1 Ferring International Pharmascience Center US $98.00 08/13/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655227883
Principal investigator 1 AbbVie, Inc. $4,632.00 08/02/2019 Non-covered Recipient Entity
Pharmax Research Clinic
M16-100 No dispute reported 06/30/2026 647588927
Principal investigator 1 Ferring International Pharmascience Center US $2,044.80 07/26/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655227775
Principal investigator 1 AbbVie, Inc. $6,083.80 07/15/2019 Non-covered Recipient Entity
Pharmax Research Clinic
M16-100 No dispute reported 06/30/2026 647588923
Principal investigator 1 Eisai Inc. $3,615.00 07/09/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530727
Principal investigator 1 Eisai Inc. $1,175.00 07/09/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530729
Principal investigator 1 Eisai Inc. $4,355.00 07/09/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530731
Principal investigator 1 Ferring International Pharmascience Center US $5,821.20 07/02/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655227563
Principal investigator 1 AbbVie, Inc. $803.60 06/20/2019 Non-covered Recipient Entity
Pharmax Research Clinic
M16-100 No dispute reported 06/30/2026 647588921
Principal investigator 1 Ferring International Pharmascience Center US $64.00 06/20/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655227515
Principal investigator 1 Ferring International Pharmascience Center US $4,375.00 06/18/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655227513
Principal investigator 1 Ferring International Pharmascience Center US $310.00 06/07/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655227477
Principal investigator 1 Eisai Inc. $1,836.00 05/30/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530717
Principal investigator 1 Eisai Inc. $3,827.00 05/30/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530719
Principal investigator 1 Eisai Inc. $3,818.00 05/30/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530721
Principal investigator 1 Eisai Inc. $1,625.00 05/30/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530723
Principal investigator 1 Eisai Inc. $3,827.00 05/30/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530725
Principal investigator 1 Ferring International Pharmascience Center US $49.00 05/28/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655227377
Principal investigator 1 AbbVie, Inc. $12,743.70 05/16/2019 Non-covered Recipient Entity
Pharmax Research Clinic
M16-100 No dispute reported 06/30/2026 647588919
Principal investigator 1 Eisai Inc. $3,615.00 05/07/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530733
Principal investigator 1 Eisai Inc. $3,818.00 05/07/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530735
Principal investigator 1 Eisai Inc. $1,625.00 05/07/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530737
Principal investigator 1 AbbVie, Inc. $12,165.60 04/16/2019 Non-covered Recipient Entity
Pharmax Research Clinic
M16-100 No dispute reported 06/30/2026 647588917
Principal investigator 1 Ferring International Pharmascience Center US $145.00 04/16/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655227173
Principal investigator 1 Ferring International Pharmascience Center US $8,488.00 04/09/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655227169
Principal investigator 1 Ferring International Pharmascience Center US $4,900.50 04/08/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655227163
Principal investigator 1 Eisai Inc. $1,836.00 04/02/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530739
Principal investigator 1 Eli Lilly and Company $703.74 03/26/2019 Non-covered Recipient Entity
INTEGRATED CLINICAL TRIAL SERVICES INC
ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 654292941
Principal investigator 1 Ferring Pharmaceuticals AS $8,206.20 03/26/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655228993
Principal investigator 1 AbbVie, Inc. $13,557.20 03/22/2019 Non-covered Recipient Entity
Pharmax Research Clinic
M16-100 No dispute reported 06/30/2026 647588913
Principal investigator 1 Ferring Pharmaceuticals AS $145.00 03/15/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655228961
Principal investigator 1 Eisai Inc. $3,818.00 03/12/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530627
Principal investigator 1 Eisai Inc. $1,625.00 03/12/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530629
Principal investigator 1 Eisai Inc. $3,827.00 03/12/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530631
Principal investigator 1 Eisai Inc. $1,836.00 03/12/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530633
Principal investigator 1 Eisai Inc. $1,524.00 03/12/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530635
Principal investigator 1 Eisai Inc. $2,495.00 03/12/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530637
Principal investigator 1 Eli Lilly and Company $18,081.60 03/12/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 654294199
Principal investigator 1 Ferring Pharmaceuticals AS $94.00 03/05/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655228893
Principal investigator 1 Ferring Pharmaceuticals AS $16,195.50 02/20/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 655228837
Principal investigator 1 AbbVie, Inc. $1,000.00 02/07/2019 Non-covered Recipient Entity
Pharmax Research Clinic
M16-100 No dispute reported 06/30/2026 647588909
Principal investigator 1 AbbVie, Inc. $5,000.00 02/07/2019 Non-covered Recipient Entity
Pharmax Research Clinic
M16-100 No dispute reported 06/30/2026 647588911
Principal investigator 1 Eisai Inc. $1,836.00 01/24/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530619
Principal investigator 1 Eisai Inc. $2,495.00 01/24/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530621
Principal investigator 1 Eisai Inc. $1,713.00 01/24/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530623
Principal investigator 1 Eisai Inc. $2,020.00 01/24/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530625
Principal investigator 1 AbbVie, Inc. $37,046.50 01/18/2019 Non-covered Recipient Entity
Pharmax Research Clinic
M16-100 No dispute reported 06/30/2026 647588915
Principal investigator 1 Eli Lilly and Company $750.00 01/15/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 654297127
Principal investigator 1 Eisai Inc. $3,615.00 01/03/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530613
Principal investigator 1 Eisai Inc. $1,524.00 01/03/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530615
Principal investigator 1 Eisai Inc. $3,002.00 01/03/2019 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702530617